U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812637) titled 'Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: a Randomized Controlled Trial' on Feb. 02.
Brief Summary: Study effeciency and safety of WJ-MSC derived exosomes in DFU healing
Study Start Date: April 06, 2024
Study Type: INTERVENTIONAL
Condition:
Diabetic Foot Ulcer (DFU)
Exosomes
Intervention:
DRUG: WJ-MSC- Exosomes
warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC
COMBINATION_PRODUCT: SOC (Standard of care)
Wound depridement for necrotic parts , local antibiotic , dressing , unloading
OTHER: Vehicle (placebo)
Vehicle for t...